Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OCT- clear · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Investigational Product #1 (IP1) | EXPERIMENTAL | octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear |
| Investigational Product #2 (IP2) | EXPERIMENTAL | octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted |
| Active Control | ACTIVE_COMPARATOR | ChloraPrep® - Hi-Lite Orange® applicator |
| Negative Control | PLACEBO_COMPARATOR | sterile 0.9% saline applied with single use applicator |
| Name | Type | Description |
|---|---|---|
| OCT - clear | DRUG | Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear |
| OCT- tinted | DRUG | Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted |
| ChloraPrep | OTHER | Active Control: ChloraPrep® - Hi-Lite Orange® applicator |
| Saline | OTHER | Negative Control: sterile 0.9% saline applied with single use applicator |
Inclusion Criteria: * Subjects may be of either sex, at least 18 years of age and of any race. * Subjects must be in good general health. * Subjects must read and sign an Informed Consent Form, Authorization to Use and Disclose Protected Health Information Form, and the List of Restricted Products ...
OCT-clear is used for preoperative skin preparation, a procedure to reduce bacteria on the skin before surgery. It is being developed by Becton, Dickinson and Company (BDX) as a small molecule treatment in the dermatology therapeutic area. The drug is currently in Phase 2 clinical development.
OCT-clear is a small molecule antimicrobial agent. Its specific molecular target has not been disclosed. The drug is designed for preoperative skin preparation to reduce microbial load on the skin prior to surgical procedures.
OCT-clear is developed by Becton, Dickinson and Company, a medical technology company traded on the New York Stock Exchange under the ticker BDX. The company is conducting clinical trials to evaluate the drug's effectiveness for preoperative skin preparation.
OCT-clear is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, evaluating the drug's effectiveness for preoperative skin preparation in healthy volunteers.
OCT-clear has one completed clinical trial, NCT03224299, titled "Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation." This Phase 2 study enrolled 131 participants in the United States, was randomized, double-blind, and placebo-controlled, and included healthy volunteers aged 18 years and older.
OCT-clear is the primary name for this investigational drug. No alternative names have been reported for this asset. It is being studied under the clinical trial identifier NCT03224299 for preoperative skin preparation.